Fig. 4: Circulating host and therapeutic antibodies in EBOV-challenged and treated rhesus macaques. | Nature Communications

Fig. 4: Circulating host and therapeutic antibodies in EBOV-challenged and treated rhesus macaques.

From: Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

Fig. 4

Circulating anti-GP IgM from rVSV-EBOV + MIL77 (a), rVSV-EBOV (b), and MIL77 (c) groups. Circulating anti-VP40 IgM from rVSV-EBOV + MIL77 (d), rVSV-EBOV (e), and MIL77 (f) groups. Circulating anti-VP40 IgG from rVSV-EBOV + MIL77 (g), rVSV-EBOV (h), and MIL77 (i) groups. ELISA data are represented as mean technical replicates (n = 2) where change in absorbances at 450 nM subtracted from baseline at day −1 (a–i). Circulating MIL77 concentrations for the rVSV-EBOV + MIL77 and MIL77 groups are represented over time (j). rVSV-EBOV + MIL77 (n = 5), rVSV-EBOV (n = 5), MIL77 (n = 5), control (n = 1). Significance of concentration differences between rVSV-EBOV + MIL77 and MIL77 only groups (***p < 0.001) were determined with two-tailed t-tests using Holm–Sidak correction for multiple comparisons. Source data are provided as a Source data file.

Back to article page